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sider the perspectives of different stakeholders (patients, 
health care payers, health care professionals, and manu-
facturers) on the provision of a research-enabled, patient-
focused molecular diagnostics platform that supports opti-
mal patient care. Through the discussion of specific case 
studies, and building on the experience from countries that 
have successfully integrated molecular diagnostics into 
clinical practice, this article will discuss the necessary evolu-
tions in policy and health technology assessment to ensure 
that patients can have equal access to appropriate molecu-
lar diagnostics.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 The recently adopted EU Council Conclusions on Per-
sonalised Medicine for Patients  [1] refer to personalised 
medicine as ‘a medical model using characterisation of 
individuals’ phenotypes and genotypes (e.g. molecular 
profiling, medical imaging, lifestyle data) for tailoring the 
right therapeutic strategy for the right person at the right 
time, and/or to determine the predisposition to disease 
and/or to deliver timely and targeted prevention’. In this 
respect, personalised medicine has the potential to opti-
 Key Words 
 Europe · Health technology assessment · Molecular 
diagnostics · Patient access · Personalised medicine · 
Policy · Reimbursement 
 Abstract 
 Molecular diagnostics can offer important benefits to pa-
tients and are a key enabler of the integration of person-
alised medicine into health care systems. However, despite 
their promise, few molecular diagnostics are embedded 
into clinical practice (especially in Europe) and access to 
these technologies remains unequal across countries and 
sometimes even within individual countries. If research 
translation and the regulatory environments have proven 
to be more challenging than expected, reimbursement and 
value assessment remain the main barriers to providing pa-
tients with equal access to molecular diagnostics. Unclear or 
non-existent reimbursement pathways, together with the 
lack of clear evidence requirements, have led to significant 
delays in the assessment of molecular diagnostics technolo-
gies in certain countries. Additionally, the lack of dedicated 
diagnostics budgets and the siloed nature of resource allo-
cation within certain health care systems have significantly 
delayed diagnostics commissioning. This article will con-
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mise the timely delivery and dosing of treatments so that 
patients can receive the most benefit for the least amount 
of risk and harm, minimising both the unnecessary side 
effects of potentially toxic treatments such as chemother-
apy and the delays associated with the ‘trial-and-error’ 
process that many patients endure to obtain the correct 
diagnosis and treatment for their condition  [2] .
 Molecular diagnostic testing plays a key role in person-
alised medicine, as it is embedded at every stage of the 
treatment pathway – from providing reliable information 
that informs the optimal treatment for the individual pa-
tient to precise monitoring of its effectiveness. Molecular 
diagnostics identify particular biological traits – often 
within the genome of the disease tissue of individuals – 
that can underpin diagnoses, prognoses, or predictions
of disease recurrence. Molecular technologies can be en-
ablers of a personalised medicine care plan, as they help 
classify disease subtypes and identify patients most likely 
to respond to a particular therapeutic or preventative mo-
dality while sparing those who will not benefit from side 
effects and potential costs  [3] .
 Despite their widely recognised promise, the use of 
molecular diagnostics in clinical practice across Europe is 
still limited. Health care systems in Europe are not de-
signed to support personalised medicine approaches and 
related innovative diagnostic technologies  [4] . This is re-
flected in a lack of appropriate patient access and clear 
pathways for reimbursing molecular diagnostics. Al-
though the results of molecular diagnostic tests can help 
influence therapy selection, reimbursement of these tests 
is limited. New pricing and reimbursement models which 
reward innovation and value and are transparent are ur-
gently needed in order to ensure that patients can benefit 
from the results of these tests and receive equitable care 
leading to improved clinical outcomes  [3] .
 Assessing the Value of Molecular Diagnostics in 
Europe 
 Benefits and Challenges to Patients, Physicians, and 
Payers 
 Molecular diagnostics offer important benefits to pa-
tients, physicians, and payers, because they can provide 
patients with the use of safer and more effective therapies 
as well as increased confidence about treatment deci-
sions. For example, KRAS mutation testing can support 
patients with metastatic colorectal cancer (CRC) and 
their physicians in making informed decisions about ef-
fective treatment  [5] .
 However, in order to allow patients to fully benefit 
from molecular diagnostics, some important concerns 
need to be addressed, such as the need for patients in Eu-
rope to have equal access to these new technologies. In 
addition, clear communication about the information 
provided by these new technologies is key in order to al-
low a patient to make informed decisions about his/her 
treatment. This information must be patient adapted, and 
patients must be involved in the preparation of appropri-
ate print and online materials.
 From a physician’s viewpoint, molecular diagnostics 
can provide physicians with information to assess risks 
and make the best treatment decisions for individual pa-
tients. Additional benefits perceived by physicians are the 
potential reduction of medical errors through person-
alised approaches and potentially a reduction of treat-
ment costs  [6] . A concern to physicians involves person-
alised medicine being seen as too disruptive, since it often 
leads to changes in current clinical practice (e.g. change 
in prescription behaviour). In order to incorporate the 
benefits into daily practice and patient care, and to ad-
dress health care professionals’ concerns, it is key that tar-
geted education programmes for health care profession-
als are developed and implemented  [7] .
 By personalising and optimising treatment, the use of 
molecular diagnostics brings the promise of more cost-
effective health care, supporting sustainable health care 
systems. Access to personalised medicine and related new 
diagnostic technologies can help eliminate many ineffi-
ciencies, such as trial-and-error dosing, the potential for 
increased hospitalisation time due to adverse drug reac-
tions, and the problem of late diagnoses. It may also en-
hance the effectiveness of therapies through better-tai-
lored treatment administration.
 However, personalised medicine also raises concerns 
and questions from payers. In a context of health care 
budget restrictions, payers are anxious about any budget 
impact that these new technologies may have. In particu-
lar, they ask that cost-effectiveness be demonstrated and 
are concerned that new targeted therapies – because they 
address a smaller population – may ultimately become 
more expensive. Finally, in most countries, health tech-
nology assessment (HTA) bodies currently lack the ca-
pacity to address this new complexity, and clear reim-
bursement pathways to allow timely and equitable access 
for patients have not yet been established. Payers’ and 
HTA agencies’ considerations about personalised medi-
cine have been described in detail in a recent publication 
from the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) Working Group on 
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Personalised Medicine  [8] . Given the important benefits 
from molecular diagnostics, including their cost-effec-
tiveness, the challenges faced by payers and HTA agencies 
need to be addressed with reliable and robust evidence.
 A Need for Clear and Efficient Reimbursement 
Pathways 
 An important cause of limited access to and use of mo-
lecular diagnostics across Europe is a lack of clear reim-
bursement pathways. Pricing and reimbursement deci-
sions are made at the country level, and this seems un-
likely to change in the near future. In many countries, 
reimbursement pathways are either lacking or are not 
clearly defined, for instance in Germany (see Box 1). 
Where reimbursement pathways exist, they usually in-
volve complex and time-consuming processes, for in-
stance in France (see Box 2).
 
 There is an urgent need to clarify and streamline nation-
al reimbursement pathways and processes, but also to en-
sure that the perspective of key stakeholders is being fully 
considered in those discussions. 
 A Need for a Dedicated HTA Framework 
 In order to truly realise the potential of these new di-
agnostic technologies in Europe, HTA processes need to 
be adapted. In most European countries, HTAs are used 
to inform funding and reimbursement decisions. With-
out developing an understanding of citizens’ concerns 
and expectations, HTA agencies and decision-makers 
may miss major drivers and barriers to the successful in-
tegration of personalised medicine into routine care. Un-
fortunately, current HTAs are rarely concerned with as-
sessing the wider societal benefits and risks of health tech-
nologies and services. Without recognising these wider 
aspects of the proposition of a societal value of person-
alised medicine, suboptimal incentivisation of corre-
sponding innovation activity is a likely consequence  [3] . 
A new and broader definition of value, which explicitly 
includes the full benefits from personalised medicine and 
molecular diagnostics, needs to be developed and inte-
grated into HTA, pricing, and reimbursement systems 
 [11–13] . In this respect, patients’ involvement in HTA 
and reimbursement is key  [14] , as described in the related 
section below.
 In addition to this, there needs to be a clear framework 
defining the assessment of molecular diagnostics. Evi-
dence requirements and criteria for decision-making of 
HTA bodies should be clearly established. HTA processes 
would benefit from being tailored specifically to the ways 
in which diagnostics are developed and tested. In particu-
lar, there should be specific requirements for evidence 
generation. First, the evidence level grid should be made 
specific to the development of diagnostics, as such tech-
nologies are developed using different methodologies 
and they have shorter cycles of development, which needs 
to be taken into account to allow health care systems to 
keep pace with innovation. Secondly, while traditional 
cost-effectiveness analysis conducted as part of HTA fo-
cuses on three key elements – i.e. (1) life years gained, (2) 
improvements in patient quality of life, and (3) cost sav-
ings within the health care system – these need to be re-
evaluated to take into account other dimensions of value 
that are specific to the molecular diagnostics pathway, 
such as increased certainty in treatment decision-making, 
the so-called value of knowing  [11–13] . This issue, how-
ever, requires further research before it can be accurately 
captured, and it is being discussed elsewhere  [15] . Finally, 
Box 1
In Germany, the health care system is split into two sectors (the 
outpatient and the inpatient sector) involving separate proce-
dures and stakeholders [9]. In the inpatient sector it is expected 
that hospitals fund the new diagnostic test from their existing 
budget until a new code and a new tariff are established. Be-
cause this process can take at least 3 years, it significantly limits 
the introduction of new diagnostics, especially if the price of a 
diagnostic is relatively high. An innovation funding pathway 
exists (NUB, i.e. Neue Untersuchungs- und Behandlungs-
methoden); however, it is rarely granted to new diagnostic tests 
and rather seems to be reserved for innovative medicines and 
medical devices. In the outpatient sector, the pathway to reim-
bursement is not entirely clear for diagnostics. Indeed, the Ger-
man HTA body (IQWIG) can be charged by the Federal Joint 
Committee (GBA) to start a new assessment. This, however, 
usually requires a high demand from physicians and patients 
and therefore does not happen as soon as the new diagnostic 
test is made available. Finally, for diagnostics that are employed 
in both sectors, the situation becomes even more complicated 
and sometimes ends in actual system failure.
Box 2
In France, manufacturers cannot request reimbursement for 
their diagnostic tests. Reimbursement for such technologies 
must be requested by a scientific society. Once the reimburse-
ment dossier is submitted by the scientific society/societies, it 
needs to be prioritised by the HAS (Haute Autorité de Santé) 
for an HTA. Once the assessment is completed, pricing and 
coding discussions may take place between the national payer 
(Union Nationale des Caisses d’Assurance Maladie) [10] and 
the Physicians Associations that are intending to use the diag-
nostic test. Overall, the process is quite long and not governed 
by specific timelines. This has implications for small diagnostic 
manufacturers, as many of them may not be able to sustain such 
a long process financially.
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the implementation of HTA guidance is key. In the UK, 
for example, the implementation of National Institute for 
Health and Clinical Excellence (NICE) guidance is lim-
ited by the fact that it is not legally binding for diagnostics 
 [16] . Indeed, unlike with drugs, there is no legal obliga-
tion for the National Health Service to fund new diagnos-
tics recommended by NICE. This obviously significantly 
limits the implementation of NICE guidance when it is 
related to diagnostics. There is also no monitoring in 
place to follow up on the implementation of this guidance 
in clinical practice.
 Cooperation between member states in the area of 
HTA has increased considerably over the last decade. 
This is reflected amongst other things in alliances such as 
EUnetHTA, a collaboration between European HTA or-
ganisations aiming to facilitate efficient use of resources 
available for HTA in order to create a sustainable system 
of HTA knowledge sharing and to promote good practice 
in HTA methods and processes  [17] . By means of provid-
ing guidance on the use of appropriate methodologies 
and capacities with respect to molecular diagnostics,
EUnetHTA may help to support timely access for patients 
to these technologies across Europe.
 Rewarding the Value of Molecular Diagnostics 
 Current Willingness to Pay for Molecular Diagnostics 
 It is estimated that diagnostics account for <2% of total 
health care spending but influence 60% of clinical deci-
sion-making  [18] . In both the US and the EU, molecular 
diagnostics are generally reimbursed under a cost-based, 
administered pricing system. As discussed in the previous 
section, the assessment of the value of these tests remains 
to be clarified in most health care systems. The current 
approach does not reward value creation, nor does it in-
centivise evidence generation to support the demonstra-
tion of value. As a consequence, most European patients 
are effectively denied access  [4] . Innovative molecular
diagnostics provide medical and economic value to pa-
tients, their physicians, and health care payers, and this 
should be reflected in the pricing. In most of the Euro-
pean health care systems, the willingness to pay for diag-
nostics priced according to their value remains unclear 
and often seems to be quite limited  [19] . Payers expect 
diagnostics to be cost neutral at best, and they do not seem 
to fully appreciate the value that these technologies may 
bring to clinical decision-making.
 Molecular diagnostic tests have been available in Eu-
rope for a number of years, with the vast majority being 
utilised in oncology  [19, 20] . However, there is wide-
spread recognition that a fragmented commissioning sys-
tem for these tests has led to varied access, with patients 
missing out on appropriate treatment options  [20] . In-
deed, in the case of medicines, positive reimbursement 
recommendations normally lead to a clear commission-
ing route with dedicated budget allocation. However, in 
the case of (molecular) diagnostics, positive assessment 
leading to a reimbursement recommendation does not 
necessarily come with clarity on the budget source, nor is 
a dedicated budget allocation identified. In Germany and 
the UK, it is expected that hospitals initially fund new di-
agnostic tests out of existing hospital tariffs [diagnosis-
related groups (DRGs)], and that these DRGs will then be 
increased after a period of time (e.g. when cost savings in 
other DRGs occur as the result of molecular testing). This 
system limits the integration of new tests into clinical 
practice, but it also does not incentivise manufacturers to 
generate high-quality evidence to support the value of 
their new test  [11, 12] . The overall effect of these limita-
tions to the reimbursement system is that patients have 
limited and unequal access to those new tests ( fig. 1 ). If 
these reimbursement systems were fit for purpose, diag-
nostics-enabled health care would be more cost-effective. 
Moreover, manufacturers would be more inclined to in-
vest in research to develop new tests and generate evi-
dence to demonstrate the clinical and economic value of 
these tests.
 Attention must be devoted to the issue of budget silos: 
it is not uncommon in health care for savings to occur in 
one budget but the innovation to be paid for from a dif-
ferent budget  [3] . This can lead to perverse incentives 
where the chance of a new health technology reaching 
patients becomes even less likely  [21] . Moreover, the tar-
iff payment system may lead to counterincentives for 
hospitals. This is the case for predictive molecular tests 
such as the Oncotype DX ® test for early-stage breast 
cancer  [22] . This test has the potential to pay off by re-
ducing chemotherapy use and costs, but because the
total chemotherapy cost (drugs, management of side
effects, etc.) is borne by different parties/budgets within 
the health care system, no one party has a clear incentive 
to fund the test to recoup the savings. With chemother-
apy attached to specific tariff payment from commis-
sioners, hospitals may lose revenue by receiving fewer 
chemotherapy tariffs and be penalised from a financial 
perspective. Again, better alignment between financial 
incentives and the clinical value of new molecular tests 
is needed to allow more equitable access for patients to 
these new tests.
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 Case Studies 
 Oncotype DX ® Breast Cancer Assay 
 The Oncotype DX ® breast cancer test is a 21-gene 
molecular diagnostic test which is used in early-stage 
breast cancer to inform chemotherapy decisions follow-
ing surgery. This test has been shown to be prognostic 
(prediction of breast cancer recurrence at 10 years) and 
predictive of chemotherapy benefit  [23] . Its impact on 
treatment decisions in clinical studies  [22] as well as
real-life settings  [24, 25] is well documented, leading to 
a significant reduction of the use of chemotherapy. 
There is also a wealth of evidence supporting the cost-
effectiveness of this test versus current clinical practice 
from a variety of countries  [26] . More recently, large 
prospective studies have confirmed the prospective-ret-
rospective studies that had initially supported the clini-
cal validation of this test, confirming that withdrawing 
chemotherapy in patients that had a low recurrence 
score on the Oncotype DX ® test led to excellent patient 
outcomes  [27–30] . Despite its inclusion in internation-
al and European clinical guidelines  [31–34] , and its rec-
ommendation by NICE  [35] , its reimbursement re-
mains quite limited in Europe. Genomic Health was one 
of the first diagnostic companies to implement value-
based pricing, and this proved to be very challenging for 
all the reasons explained above. Also, Genomic Health’s 
central laboratory model, which presents many advan-
tages in terms of the quality and reproducibility of the 
test, is being challenged by some of the health authori-
ties. Indeed, the transfer of value to the US is not always 
well accepted. Some countries, however, made the deci-
sion to reimburse this test early, before NICE issued its 
guidance and before the publication of prospective evi-
dence. Ireland was the first European country to reim-
burse the Oncotype DX ® test in October 2011. When 
the TAILORx trial ended its recruitment in Ireland in 
2009, the National Cancer Control Programme (NCCP) 
asked the National Centre for Pharmacoeconomics 
(NCPE) to assess the Oncotype DX ® test. The HTA and 
the pricing negotiations were completed within 9 
months, and the positive reimbursement decision 
proved to be cost-effective as it led to significant savings 
EUR
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EUR
1,853,940
EUR 793,565
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4,000,000
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 Fig. 1. Effects of limitations to reimburse-
ment systems. Budget silos and counterin-
centives of tariff payment systems. 
 Fig. 2. Economic impact of the use of the Oncotype DX ® test in 
Ireland. 
D
ow
nl
oa
de
d 
by
: 
 
Qu
ee
n's
 U
niv
er
sit
y B
elf
as
t M
cC
lay
 L
ibr
ar
y  
   
   
   
  
14
3.
11
7.
19
3.
89
 - 
11
/1
/2
01
7 
3:
42
:2
9 
PM
 Equal Access to Molecular Diagnostics Public Health Genomics 2016;19:144–152
DOI: 10.1159/000446532
149
for the Irish Department of Health, as shown in  figure 2 
 [25] . This positive experience was even shared in a con-
ference that took place in 2013 under the auspices of the 
Irish EU presidency  [3] .
 The province of Ontario in Canada decided to reim-
burse the Oncotype DX ® test in 2010 following an HTA 
conducted by the Ontario Health Technology Advisory 
Committee (OHTAC)  [36] . Because the HTA report 
raised some uncertainties related to the expected impact 
of the test in real-life clinical practice, the province of
Ontario decided to conduct a field evaluation in order to 
address this question and to revisit the cost-effectiveness 
evaluation based on the findings from the field evalua-
tion. The results from this study showed that the test led 
to a 53% change in treatment decisions (with a 38% re-
duction in the use of chemotherapy)  [24] , and the cost-
effectiveness analysis  [37] indicated that using the test 
was cost-effective. These results confirmed the original 
decision made by the province of Ontario, and since then 
patients continue to have access to the Oncotype DX ® 
test.
 KRAS Companion Diagnostic 
 CRC is one of the most common cancers worldwide. 
With the emergence of two anti-epidermal growth fac-
tor receptor (EGFR)-targeted antibodies, cetuximab 
(Erbitux) and panitumumab (Vectibix), the treatment 
of metastatic CRC has entered into the era of person-
alised treatment. However, EGFR, the target of these 
drugs, which is overexpressed in approximately 80% of 
colorectal carcinomas, failed to predict a therapeutic re-
sponse when used clinically. The KRAS gene has been 
demonstrated to be a strong negative predictive bio-
marker to indicate whether a CRC patient will respond 
to anti-EGFR treatment. As the target treatment may 
also be toxic and expensive, KRAS mutation status de-
tection has become a crucial diagnostic factor for treat-
ing metastatic CRC patients  [38] . A decision of the 
French public health insurance system to provide tar-
geted therapy for CRC, together with a joint initiative 
between the National Cancer Institute (INCa) and the 
French Ministry of Health, has had a positive impact on 
access to KRAS testing in France, as discussed in Box 3. 
The French screening and targeted cancer treatment ini-
tiative offers equal access to molecular testing for all pa-
tients in France and represents a real benefit in terms of 
public health. It illustrates that molecular stratification 
can be successfully integrated into the health care system 
and, as an additional benefit, is a cost-effective strategy 
 [39, 40] .
 Policy and HTA Implications for More Equitable 
Access to Molecular Diagnostic Tests in Europe 
 Greater Involvement of Patients 
 To realise the potential of molecular diagnostics in
Europe, access to these technologies urgently needs to
be improved. In order to achieve this, funding and re-
imbursement systems need to be adapted and move from 
a ‘fee per service’ towards a ‘value-based’ approach, re-
warding patient outcomes. Achieving the best results for 
patients should be the highest priority. The voice of pa-
tients should therefore be represented in HTA and reim-
bursement processes and reflected in ultimate decisions, 
in particular at a time when new (disruptive) technologies 
Box 3
In order to ensure wide access to molecular tumour profiling, 
INCa and the Ministry of Health set up a national network of 
28 regional molecular genetics centres in 2006, aiming at uni-
form nationwide test provision and fast implementation of mo-
lecular tests for new tumour biomarkers, including KRAS mu-
tation testing. With the aim of serving as a regional hub for 
expert molecular testing, each molecular genetic centre is based 
on a partnership between several university hospital and cancer 
centre laboratories with complementary expertise. Each labo-
ratory developed KRAS testing according to its own expertise 
and to the locally available technology platform [39, 40]. INCa 
is responsible for coordinating the 28 regional molecular genet-
ics centres at the national level; the network is funded by INCa 
and the Ministry of Health. During the setup phase, INCa al-
located EUR 4.7 million for the purchase of equipment; this 
initial funding was followed by the allocation of EUR 4 million 
in annual funding to the centres and staff from the French Min-
istry of Health. Additional, specific funding was required fol-
lowing the authorisation of panitumumab and cetuximab for 
patients with wild-type KRAS, because a sharp increase in mo-
lecular testing activity was expected. INCa allocated an addi-
tional EUR 2.5 million for KRAS mutation screening to the 
2008 budget. INCa used quarterly reports to monitor the activ-
ity of the centres and to adjust the overall budget and its alloca-
tions accordingly. This additional funding was then followed 
by recurrent annual funding from the French Ministry of 
Health [40]. A sharp increase in KRAS and EGFR mutation 
screening of colorectal and lung cancers was seen after anti-
EGFR and EGFR tyrosine kinase inhibitor therapy approvals. 
In 2009, 17,250 patients benefited from KRAS mutation screen-
ing, compared to only 1,100 in 2007. The activity has stabilised 
as expected since 2010, with KRAS testing of 16,581 patients in 
2010 and 17,003 patients in 2011. A range of studies have indi-
cated the cost-effectiveness of KRAS testing. For example, 
KRAS testing avoids a median of 8 months of ineffective cetux-
imab therapy in patients with KRAS mutations that would cost 
EUR 32,419 per patient in France [40].
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offer important opportunities for patients. The represen-
tation of patients in reimbursement processes may still be 
considered limited  [41] .
 In addition, in most HTA and reimbursement pro-
cesses in Europe, patients are not directly represented. 
Apart from financial resource constraints, the main chal-
lenges regarding patients’ involvement are perceived to 
be the lack of capacity, time, and good methodologies 
 [14] . Yet, patients have valuable perspectives and experi-
ence that can inform HTA and decision-making, helping 
to explain what it is like to live with a particular condition 
and shedding light on their experience with current tech-
nologies and what they would value most in a new treat-
ment. In the appraisal phase of HTA, patient evidence can 
inform discussions about the added value of a new tech-
nology and generally inform the value judgements of
researchers and decision-making committees. Active in-
volvement of patients will result in technology assess-
ments of higher quality compared to those currently 
performed, maximising the potential for a technology’s 
adoption and implementation  [2] . There are initiatives at 
the EU level aiming to ensure patients’ interests are rep-
resented in a meaningful way in HTA and reimbursement 
discussions. These are driven by European patient organ-
isations (such as the European Patients’ Forum  [14] and 
EURORDIS Rare Diseases Europe  [42] ) and by projects 
such as ADAPT SMART  [43] , which seeks to establish 
collaborative solutions to foster the development of Med-
icines Adaptive Pathways to Patients (MAPPs)  [44] , aim-
ing to provide patients with more appropriate access to 
innovative medicines. The European Patients’ Academy 
on Therapeutic Innovation (EUPATI) project on the oth-
er hand focuses on capacity building to enhance patients’ 
knowledge and enable them to engage effectively in ther-
apeutic R&D  [45] . These initiatives focus mostly on me-
dicinal products, but they could potentially be extended 
to include medical/diagnostic technologies.
 Clearer Reimbursement Pathways Including Evidence 
Requirements 
 Reimbursement of molecular diagnostic tests in Eu-
rope is challenging for a variety of reasons. Most impor-
tantly, only few reimbursement or uptake decisions are 
made based on value – reimbursement is generally based 
on lump sums for health care institutions and laborato-
ries, with cost and price being the only criteria. A dedi-
cated and specific value-based reimbursement pathway 
for innovative (molecular) diagnostic technologies needs 
to be developed and implemented consistently across Eu-
rope, ensuring equal access for patients. In order for these 
pathways to be effective, it is essential that clear evidence 
requirements are set. Different health care systems in Eu-
rope ask for different and increasing evidence of the value 
that diagnostic technologies contribute. Decision-mak-
ers, including HTA bodies, informed by input from pa-
tients, should define the key value outcomes they seek 
from diagnostic technologies and should commit to pay 
for them  [46] .
 Better Implementation of HTA Guidance 
 Once HTA processes have been adapted to include the 
interests of patients and appropriate methods and skills 
to evaluate innovative molecular diagnostics are in place, 
there is a need to ensure that the resulting guidance is ac-
tually implemented. In many countries, HTA processes 
do not automatically lead to funding or reimbursement 
decisions  [16] . It is therefore key to ensure that published 
HTA guidance results, if positive, lead to a clear commis-
sioning route with a dedicated budget. This can be 
achieved through better alignment of the HTA and the 
commissioning process and by making the HTA guid-
ance legally binding, at the same time monitoring its im-
plementation into clinical practice.
 Coverage with Evidence Development 
 Coverage with evidence development may offer op-
portunities for earlier patient access to innovative mo-
lecular diagnostic tests. Indeed, conditional/temporary 
reimbursement of new technologies against data collec-
tion from providers could be a solution to facilitate rapid 
and safe patient access. Coverage with evidence develop-
ment is usually implemented when there is either a need 
to manage utilisation in real-world situations or to pro-
vide evidence in order to address the uncertainty of the 
reimbursement decision  [47] . Assuming that the process 
of data collection being requested against reimbursement 
is not too cumbersome for providers, this may be a solu-
tion for earlier access for patients that also satisfies payers’ 
and manufacturers’ expectations. As presented in the
Oncotype DX ® case study earlier, conditional reimburse-
ment was successfully implemented by the province of 
Ontario in Canada. This positive experience could be rep-
licated in other countries.
 Conclusions 
 In the area of molecular diagnostics, further reform is 
needed to ensure patients can realise benefits from these 
tests and receive equal access leading to the best possible 
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clinical outcomes. Clear reimbursement pathways and 
evidence requirements, together with a systematic im-
plementation of reimbursement recommendations fol-
lowing HTA, are needed. Moreover, conditional reim-
bursement of further data collection may be a solution to 
allow earlier access for patients while enabling payers to 
receive the answers to some of the key questions they 
may have on the real-life impact of (molecular) diagnos-
tics. Finally, it is key that patients are involved more in 
value assessment via HTA as well as in reimbursement 
discussions.
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